Member Info for Ezzza

Bignose
OMG…….I was trying to find the source of my info regarding Dr Mike and his working on V2 when I came across the document from which I posted info from this morning.
However, I was concentrating on finding the source of the info which was a document produced by Dr Mike/ RP.
Having posted the link for you to look at this I realised that this has come from the 2017 Master Investor seminar. This seminar is held annually usually in London and there are various speakers “peddling their wares” in an attempt to get us mere mortals to invest some of our hard earned into them. For instance, Jim Mellon is a regular speaker here.
If you Google Dr Mike Wyllie master investor 2017 show there is actually a picture of him giving the presentation to an audience of potential investors (I can’t download it) but this presentation document is there and the content of this must have formed his presentation. And at the end is all of the info which I posted this morning and therefore must have been part of the “sales pitch”
Bignose…..here is your proof to take to Gibson as taken from the Master Investor Website. This has Dr Mikes picture next to it…..so I would say “guilty m’lud” and please note the last paragraph which ties into the V2 comments in the presentation document
PROFESSOR MICHAEL GRANT WYLLIE, PHD, DSC, CHIEF SCIENTIFIC OFFICER, REGENT PACIFIC GROUP; EXECUTIVE DIRECTOR, PLETHORA SOLUTIONS LTD.
Regent Pacific Group Limited | 14:05 – 14:15
Talk Title: Regent Pacific a major player in Sexual Health today and tomorrow.
Prof Wyllie has particular responsibility for the process of securing approvals of the product, regulatory compliance and assisting the Chief Executive Officer in the commercial development of Fortacin of Plethora Solutions Holdings plc (“Plethora”). Prof Wyllie is a co-founder of Plethora. He has over 30 years of experience in senior management level positions within the pharmaceutical industry, with Wyeth and Pfizer. He has considerable hands-on experience in all aspects of the drug discovery and development process, and has been involved with new project inception, drug discovery and safety testing, early and late stage clinical development, regulatory filing, and the successful commercialisation of products, including Cardura® (doxazosin), Enablex® (darifenacin) and Viagra® (sildenafil). Prof Wyllie sits on the Clinical Trial Design and Future Therapies in BPH Committees of the World Health Organisation International Consultations on Urological Disease and the International Advisory Panel to The University of Strathclyde. He is an assistant editor of the British Journal of Urology in the Sexual Medicine Section. He has over 200 publications and is the named inventor of over 80 patents. He is an independent director on the board of the NASDAQ listed reproductive health company, Repros (RPRX).
The talk will feature predominantly on activities within Plethora Solutions covering the EU launch by Recordati and progress on US submi

Bignose.

It doesn't appear to be on the RP website (no surprise in that then). However you can't keep anything away from Google so here is the link that takes you straight to the document. Enjoy.

https://masterinvestor.co.uk/wp-content/uploads/2017/04/MI_2017_Professor_Michael_Grant_Wyllie_-_Regent_Pacific_Group.pdf

Hi Alq.
If you would care to stand for election to the board of RP at the next AGM I would take you anytime over Gibson. At least we will get some informative dialogue for shareholders and we will have someone on the board that does appear to have a clue.
However, the downside my friend: Huge reduction in the basic salary but superb profit related pay, HK Bus Pass with 1st class seating and we can throw in a new Samsung Galaxy S9 so that you can easily keep in touch with us mushrooms.
How about it Alq?? Go on…you know it makes sense!!!!

continued

§  Many of these can be treated by e.g. prostaglandins (Caverject or Edex)but this involves direct injection into the penis and there is a 30% incidence of pain at the injection site. There is an alternative using a mixture of VIP and phentolamine that is approved in several EU countries but this also involves intra penile injection.
§  There is a high probability that Regent proprietary technology similar to that used in Fortacin will lead to the development of a topical delivery formulation of this agent. The track to market or more realistically out-licensing will be relatively fast as 505(b)2 and there will be premium pricing as therapy for a special needs population. IP protection will be at least 15 years.
Conclusion
A focussed healthcare investment vehicle listed on the main board of the Hong Kong Stock Exchange
§  Unique opportunity to participate in a high growth story with the defensive quality of a healthcare investment in a volatile global equity market
§  Core product Fortacin™ is a European approved treatment for Premature Ejaculation and it has the potential to be the next Viagra in a market that could be worth up to US$3 billion per annum
§  Now available for sale in the UK by way of prescription and expected to launch in Europe in 2017 by Recordati S.p.A tapping into a PE market which affects 1 in 4 men
§  Michael G Wyllie, the scientist behind Viagra and Fortacin™ will continue to provide scientific oversight and input on the development of Fortacin™ and valuate/ identify other exciting ‘late stage’ investments

Hi Bignose.
I had a quick search on the internet to see if I could find the source of my info regarding Dr Mike and V2. I seem to remember something about V1 appeared not work on guys with a low Testosterone level and those with severe Diabetes (this last point is to some degree confirmed below). I will have another look when I get back from work. However, I did find the following which was copied from RP, was produced by Dr Mike and was produced just 18mths or so ago.
It reads to me as though they are well down the line with V2 when you take into account the product has been designated the code 505b2, must have been designed and or tested when you take the following into account: . “Regent proprietary delivery technology should result in topically active therapy” and there appears to be a plan of action (don’t hold your breath on that one): “Fast track to market (out licensing as 505b2). Could be out-licensed within 2years”
And
“There is a high probability that Regent proprietary technology similar to that used in Fortacin will lead to the development of a topical delivery formulation of this agent. The track to market or more realistically out-licensing will be relatively fast as 505(b)2 and there will be premium pricing as therapy for a special needs population. IP protection will be at least 15 years”
If JG is now stating there is nothing in the pipeline now then this is clearly at odds with Dr Mike’s overview below. Which then begs the questions “why not and what happened”?
Regent Pacific Group Limited
COMPANY OVERVIEW 25 MARCH 2017 Dr Mike Wyllie
Pipeline Opportunities
Viagra/Cialis (PDEi) Failures
Current Landscape
§  Global sales for Viagra/Cialis and now generics in excess of $3billion pa.
§  Now accepted that almost half of patients receiving Viagra don’t’ respond (particularly diabetics).
§  Arrival of generics has increased number of patients receiving Viagra (and failing to respond).
§  Many non responders will respond to intra penile injection of prostaglandins but pain at injection site.
§  Approved injection in certain EU countries of Invicorp (VIP +phentolamine) with most non responders responding.
§  Sales potential not realised as injection. Regent proprietary delivery technology should result in topically active therapy.
§  Fast track to market (out licensing as 505b2). Could be out-licensed within 2years.
§  Premium pricing as special needs and IP advantage.
Viagra/Cialis (PDEi) Failures
Commercial Opportunity
§  The major remaining commercial opportunity in sexual health is for treatment of Viagra/Cialis failures. Almost 50% of ED patients, particularly diabetics, fail to respond adequately to PDE inhibitors.
§  Many of these can be treated by e.g. prostaglandins (Caverject or Edex)but this involves direct injection into the penis and there is a 30% incidence of pain at the injection site. There is an alternative using a mixture of VIP and phentolamine that is approved in se

Hi Bothwell
sorry to be a pain in the arris but as you are in contact with JM I wonder if the info below is a golden opportunity for him to promote RP/Fortacin for the benefit of all shareholders.

I am sure you will all notice the comment about the "money fountain" as I seem to think I have heard this somewhere before. Also, as I mentioned in my first post today JM's concentration has moved into Bio with the takeover of SalvRX by Portage both of which JM is a board member. Nice one Jim and yet another money fountain being drilled.

So Bothwell. As JM is offering his detailed knowledge/acumen/advice to everyone willing to shell out £300 on the next "money fountain" which is clearly Bio related investments could you ask him to drop in a word or more into his lecture about RP and Fortacin as it is clear that as we will be living much longer than now then those who struggle with "holding it back" will clearly need our product throughout LONGEVITY i.e.longer.....and just to think that if one in four suffer this problem then Fortacin has a clear advantage sales wise for the future. Isn't that what drives share prices up???

Would you let us all know what JM's view is on this excellent opportunity RP wise.

Thu 1 November 2018 09:30 – 17:00 GMT
LOCATION
Wellcome Collection
183 Euston Road
London
NW1 2BE
£300 per ticket
Longevity is "the biggest money fountain that I have ever seen".
- Billionaire investor Jim Mellon
We are on the verge of a lifespan revolution. In the next 30 years, life expectancy is going to rise to between 110 and 120.
The nascent but rapidly growing longevity industry has the capacity to change forever how we live, and how (and when) we die. Crucially, it will also influence how we successfully invest for the future.
How can we as investors prosper in this new era of longevity?
Our one-day masterclass offers you the rare chance to be involved (and invested) in the birth of a new industry – arguably the greatest investment opportunity of all time.
Selecting the right investments is key and knowledge is fundamental. 'Investing in the age of longevity' will show you how.
• Get the inside track on the latest ageing related discoveries
• Network with some of the leading longevity scientists and investors
• Meet the businesses identified by Jim Mellon as being good investments
Start profiting from the rapid technology evolution. Sign up today.
Tickets are strictly limited and available on a first-come, first-served basis.

Hi Bothwell.
In the past I do recall JM regularly commenting on what was happening on progress within Plethora. E.g. there was the taking out of Shionogi for the global rights to PSD502 (Fortacin) his regular trips to San Francisco and his discussions on PSD502 there. I think it was at one of these meetings that Baker Bros invested a large amount in Plethora only to bail out when RP took over as they would not invest in HK companies.
But for the last few years we have had practically nothing really from him yet he was clearly the driver in moving the company forward....lately we have simple one line comments from JM on his Twitter account e.g. the “money fountain” which was quickly removed if I remember rightly and “we haven’t sold any shares”.
If JM is e-mailing you a reply to a query you have made that's good but then why can’t he or someone else from the BoD simply provide a Shareholder update on what is happening in RP. What is so difficult to provide, say, a quarterly update on the website?
For instance, JG noted that Recordati were disappointed at initial sales and that RP would be working closely with them on this. So just what are they doing together then? What plans do they have to increase sales in the countries that we are now selling Fortacin in and how do they intend to make sure that the launches in other countries result in better sales.
What are they doing Proactively???
Is that asking too much?

OOPS….thanks The.Italian as I hadn’t realised the last couple of words were missing from my last post. It should have read “yet the apathy shown by this BoD is staggering”
The frustrating thing here is that we had (have) such a great product with such huge potential which was developed by a man in Dr Mike who’s reputation in this area clearly goes before him given what he also did at Pfizer. Couple this with JM’s (then) undoubted business/financial skills and there would be only one way this could go…couldn’t it? Well if you read the extract below taken from Proactive Investor you would think so. Please note that this report is almost 5yrs old and you will note some interesting comments…particularly the ones over the (early 2014) FDA submission.
Also the last paragraph gives us some hope. In the 6mths to Nov 2013 the share price rose over 1000% and if it did that in the next 6mths we would be at around 30p per share and I would be out like a shot.

UPDATE - Plethora Solutions granted EU marketing approval
11:40 19 Nov 2013

Plethora Solutions’ treatment for premature ejaculation has been granted marketing authorisation by the EU’s executive body, the European Commission

Plethora Solutions’ (LON:PLE) treatment for premature ejaculation has been granted marketing authorisation by the EU’s executive body, the European Commission (EC).
In September, the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) advised the EC to approve PSD502, which will go under the name ‘Prilocaine Lidocaine Plethora’.
The company estimates 30-45mln men between 20 and 69 years old in the EU suffer from the sexual dysfunction.
Chairman Jim Mellon said: “Plethora was founded in 2004 to develop PSD502; in 2011 the company regained control of the European approval process and PSD502 has now been approved by the European Commission.
“In August this year Plethora regained global control of PSD502 and work is well underway to file with the FDA [US Food and Drug Administration] in early New Year.”
He continued: “We are delighted by today's news that represents an important step in the successful commercialisation of the product.
“Premature ejaculation can cause serious distress for those men who suffer from the condition and we hope that PSD502 will help them and their partners.”
Broker Daniel Stewart estimates that the group could receive approval to the US market in the second half of 2015.
It lifts its target price from 15.7p to 18.9p to reflect the lower risk associated with investing in the company now it has secured the EC approval.
“Finally, we reiterate our belief that PSD502 has the potential to go mass-market,” said the broker, which believes such an outcome would transform Plethora into a “large business”.
Plethora’s shares spiked in early deals but settled 3% higher at 17.1p. They have risen over 1,000% in the past six months.

Hi Bignose. I will try to find out were I got the info on Dr Mike & V2 from but it was definitely something I read somewhere.

As for were we are??

As taken from the August 2018 Interims:
Recordati has informed the Company that the sales of Fortacin™ uptake was lower than expected for the period, with the key issue being the low number of PE patients seeking advice and visiting a specialist for treatment (with key reasons being given due to the embarrassment and lack of awareness about treatments available for PE).

Yet from RP’s website:
PE is possibly the most prevalent sexual dysfunction affecting 1 in every 4 men globally, regardless of age, race or geography, and an estimated greater number than erectile dysfunction. Data from the National Health and Social Life Survey have revealed a prevalence of 31 per cent of men in the United States suffer from the condition, which is fairly steady through all adult age groups. A British survey estimated this number at 14 to 31 per cent. According to the Global Study of Sexual Attitudes and Behaviors survey conducted in 29 countries in men aged 40 to 80 years in 2005, the estimated worldwide prevalence of PE was about 30 per cent.
Based on internal modeling, it is believed that the PE market will in due course be worth between US$500 million and US$3 billion per annum.It was also noted that PE effects significantly more men than ED.

So the potential is huge

What are Recordati doing to increase sales of Fortacin given they appear to be disappointed with the uptake? If we are to take it that they hold seminars with Doctors in the rolled out countries detailing the benefits of Fortacin then this is product awareness for the Doctor and NOT the potential customer. Recordati go on to say “ the low number of PE patients seeking advice and visiting a specialist for treatment with key reasons being given due to the embarrassment and lack of awareness about treatments available for PE” and in this sentence they have the answer to the problem. Will they get substantial sales if there is little knowledge of the product. And for those who are embarrassed to discuss this with their doctor then the Doctor will not know of the problem.
There are approx. 30,000 GP Practices in Germany (according to Google) Could Recordati undertake a simple marketing exercise and have a poster in every GP’s surgery advertising Fortacin. Say a Euro per poster….30,000 in Germany …chicken feed to them EG there is an healthy looking guy on the poster, suntan and showing his pearly whites whilst holding a canister of Fortacin next to his smile….with a caption below saying something like…”I’ve gone from 3 seconds to 3 minutes with just one spray and the wife loves it too" ….Ask your Doctor about the clinically approved Fortacin or go to WWW….etc.
It’s a start, cost effective, has a target audience and surely isn’t difficult to execute.
Sorry for the rant but I am looking at a (paper) loss and yet the apathy shown by this

Hi Guys and Gals. Just come back from a short break and have been meaning to make my first post although I look in on a daily basis. I have been in Plethora / RP for around 7yrs now so count my 700,000 approx. shares towards "the cause". Just wanted to thank the excellent posters on here for keeping me going, particularly Bignose and obviously POM who is greatly missed as far as I am concerned. I am in another AIM share were a BB member was banned and he now e-mails his views to another BB member who then pastes his comments to the board. Maybe we can somehow try to get Pom's views this way. Special mention to Pikey Pete for making me laugh so much when everything here is so depressing. PP's classic line went something like "does a Gibson ever change it's spots"....brilliant.

I think the idea of a "Friends of Fortacin" shareholder group or something similar in order to get the BoD to treat us with respect and valued shareholders rather than mushrooms with the resulting treatment is a great idea. Maybe a polite e-mail to JM explaining who we are and why we are contacting him might do the trick. If not then maybe the same approach to Dr Mike who appears more receptive to shareholder dialogue.

In respect to JG I do have to say that his salary is laughable given were the share price is. I do wonder how they came to award him such a high level of remuneration for what appears to be a distinct lack of anything useful on his part. Job for the boys??. How are they going to sustain this given the little income coming in so far??

Given the amount of research I did on the company before I invested I just cannot believe how the BoD appear to have messed this up. Everyone was buzzing from the point that we had EU approval for a product that has huge sales potential and then.....car crash city. I wonder what Dr Mike makes of all of this? His baby,a product with no real competition, huge world wide sales potential and well....er nothing!!!. Certainly not in the UK. I hear that Dr Mike is working on Viagra 2...the tablet that will work for the 50% of peeps that Viagra 1 wouldn't. I wonder if he will be handing this over to RP when the time comes to get it to market ?? mmmmm.

Finally, it's interesting how JM had gone totally quiet on all things RP wise....not a peep, It's as though he has simply given up on the "money fountain". Or is it because his great belief in Bio Tech has seen SalvRX of which he is a member of the BoD now in the process of a takeover by a company called Portage Bio....and would you be surprised to learn that a member of that BoD's is a certain Mr James Mellon Esq....talk about a "win win". If Mr Mellon would care to put an equal amount of time and effort into RP that he clearly appears to have done with SalvRX/ Portage then we may JUST be OK.....but don't hold your breath on that one. Many millions is to be made there....whilst we shareholders of RP just sit with our fingers crossed and live in hope

All the best to all LTH's